Eli Lilly falls on a rival's obesity study — plus, we're removing 3 stocks from our watchlist
Viking falls after Roche’s obesity drug data; RayJay upgrades (update)
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Should You Hold Viking Therapeutics in Your Portfolio?
Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
Is Viking Therapeutics the Best Biotech Stock for You?
The 3 Best Russell 2000 Stocks to Buy in May 2024
Viking Therapeutics's Options Frenzy: What You Need to Know
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 72% of the company
Here Are the Obesity Drug Hopefuls Vying to Unseat Ozempic, Zepbound
What Is the Best Weight Loss Stock to Buy Now? Our Top 3 Picks
Check Out What Whales Are Doing With VKTX
Check Out What Whales Are Doing With VKTX
Is Viking Therapeutics Incredibly Undervalued?
Is Viking Therapeutics Incredibly Undervalued?
Can This High-Flying Stock 10x in 10 Years?
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.